Age-related macular degeneration (ARMD) is a major cause of blindness in the Western world. Two forms of ARMD exist: the exudative form, accounting for 12% of patients, and the dry form, accounting for the remainder. The exudative form of the disease constitutes the more visually debilitating subgroup of ARMD and accounts for 88% of these patients with ARMD who are considered legally blind. ! The prevalence of severe visual impairment due to exudative ARMD increases with age. Wilkinson and co-workers 2 estimated that 745 000 individuals over age 65 years, in the United States, have unilateral or bilateral severe visual impairment due to ARMD.
The only proven treatment for extrafoveal and juxtafoveal choroidal neovascular membrane (CNVM), as demonstrated by randomised controlled clinical trials, is laser photocoagulation ? , 4 It has since been estimated that up to 80% of patients presenting with CNVM due to ARMD do not meet the original Macular Photocoagulation Study (MPS) guidelines for treatment. s Recent subgroup analyses of laser treatment for subfoveal CNVM have shown that, although laser is beneficial for slowing the rate of severe visual loss (quadrupling of the visual angle), many eyes suffer immediate loss of vision which does not recover, and recurrences are common. 6 There are a large number of people affected by ARMD who have been treated with laser, and have had suboptimal results over time. It is for this reason that other treatment modalities have been sought, including medications, surgical removal, and other treatment methods that are known to alter blood vessel growth. Work utilising radiation therapy for ARMD began to appear in 1993 in the European literature. Based on preliminary studies by Chakravarthy et al., radiation therapy had an inhibitory effect on CNVMs demonstrated by atrophy by capillaries at the growing edge of the lesions ? -9 Pilot studies with radiation therapy in the treatment of CNVM secondary to ARMD have suggested a possible benefit. After these initial encouraging reports, the proton beam was considered as an alternative delivery method for radiation. It can be used to treat a specific region while minimising radiation to surrounding tissues. Its theoretical advantage over external beam radiation is that it allows specific focusing of concentrated radiation in the form of protons to the macula without delivering radiation to surrounding tissues or the optic nerve. Initial work with 8 CGE (CGE = Cobalt Gray Equivalent, using relative biological effectiveness of 1.1 as compared with cobalt) was carried out by Yonemoto and colleagues lO with encouraging preliminary results and no toxicity. We report our results utilising the proton beam in two dose regimens with long-term follow up.
Patients and methods
Forty-eight eyes of 46 patients with active, sub foveal CNVM due to ARMD were prospectively entered into a study at Lorna Linda University beginning in March 1994 to assess the safety, efficacy and toxicity of proton beam radiation for ARMD.
Before instigation of the study, the consent form treatment protocol was approved by the Institutional Review Board at Loma Linda University. Informed consent was obtained from all patients prior to study admission. These patients were not financially responsible for treatment charges.
Patient inclusion criteria are summarised in Table 1 , and patient characteristics are summarised in Table 2 . Thirty-one patients were female and 17 were male. All patients were over 55 years old, with an age range of 59-90 years and a mean age of 77.8 years. These patients had no history of diabetes mellitus, collagen vascular disease or other ocular vascular occlusive disease.
All patients underwent a complete ophthalmological examination and fluorescein angiography at study entrance, at 3 month intervals for the first 24 months, and then every 6 months thereafter. The examination consisted of visual acuity testing as per MPS protocol, using MPS acuity charts (Bailey-Lovie), reading speed, contrast sensitivity testing, Goldmann applanation tonometry, anterior segment examination, and a dilated fundus examination. Each aspect of the examination was carried out as follows: (1) At each visit, standard trial frame refraction was carried out at 10 feet, according to MPS protocol, using the Bailey-Lovie charts. An identical testing environment using fluorescent background illumination was employed for all study patients. Visual acuity examiners were masked to patient identity and study participation. (2) Contrast sensitivity testing was measured using a MPS contrast chart, which was an early version of the Pelli-Robson chart, in which letter size corresponded to Bailey-Lovie visual acuity of approximately 20/725 at the required testing distance. (3) Reading speed was measured by recording the time required to read 40 words of high-contrast text, subtending an angle equivalent to a Bailey-Lovie visual acuity of 20/1500 at that testing distance. Care was taken to ensure that patient positioning under background fluorescent lighting was similar in all testing sessions and that no additional reading lights were used. The study eye was always tested first, with complete contralateral eye occlusion. Three minutes were allowed for completion. ll Stereo fundus fluorescein angiography on film was obtained at each visit in a standard fashion by an experienced ophthalmic photographer (S.c.o.) with the acute phase of the angiogram taken of the study eye and late-phase photographs of both eyes. Stereo colour fundus photographs were taken of both eyes at each visit.
Eligibility criteria for CNVM are detailed in Table 1 and required that the edges of the CNVM complex, including blocked fluorescence, blood, occult CNVM and classic CNVM, be well defined and that the complex underlie the foveal centre. If blood was in the central fovea, the CNVM must surround the blood. The complexes could include classic, occult, and combinations of both classic and occult components. It was required that two of three university-based, retina trained ophthalmologists agree on fluorescein angiographic MPS lesion size, and that a patient meet study entry eligibility as defined in Table 1 . MPS overlay templates 12 were used on 35° Topcon fundus photographs to determine lesion size, which was based on the longest diameter of the lesion before treatment and at all follow-up visits. Angiographically, leakage of fluorescein in the late arteriovenous phase was taken as an indication of neovascular activity. Areas of late, well defined hyperfluorescence which showed no increase in area throughout the angiogram were felt to be compatible with fibroglial scarring when compared with the colour photographs. At follow-up, to be considered as an area of reduced leakage, there must have been a decrease in the cumulative area of late hyperfluorescence as measured using MPS overlay templates and compared with the pre-treatment angiogram.
In this study, eyes with a greater amount of blood than was protocol for MPS criteria were allowed. However, in these eyes subfoveal leakage was required. In addition, lesion complex size did not include blood at the lesion complex margin. Although this may underestimate CNVM size, resolution of blood would create an artificially favourable influence on lesion complex size, unrelated to CNVM regression.
The incidence of severe visual loss was measured by calculating the percentage of eyes with quadrupling of the visual angle (i.e. such as a change from 20/100 to 20/400 or equal to a loss of 6 lines of Snellen equivalent) from baseline. If an appointment was missed, severe visual loss was assumed to exist if it was present at the most recent test.
Eye parameters, including axial length and lesion size, were used to generate a three-dimensional computerised model of the eye upon which the treatment plan and dosimetry were based (Fig. 1) . The study was designed as a planned dose-escalation, phase I/ll investigation .. The patients were treated to a dose of 8 CGE or 14 CGE, given in a single fraction using 100 MeV protons from the Lama Linda University Medical Center synchrotron, using the technique described previously. lO The first 21 eyes were treated with a single proton beam exposure of 8 CGE. In March 1995, when no toxicity had been observed in these patients, a dose of 14 CGE protons was initiated for subsequent patients, as planned. lO The latter dose is used routinely as one of five fractions in the treatment of ocular melanomas. This is the highest dose, per fraction, commonly used.
Results
There were 21 eyes in the 8 CGE treatment group, and 27 eyes in the 14 CGE treatment group. Results are divided into the two treatment groups, and are summarised in Table 2 . The average follow-up period in both groups was 22.1 months, with a range of 3-33 months. Refractive errors ranged from -1.625 to +5.125, with no appreciable change noted during the course of study follow-up.
At study entry, all patients had CNVMs measuring greater than 0.67 disc areas in size. Forty eyes had a well defined, classic CNVM, located subfoveally. However, 5 patients had a classic CNVM, with a large occult component, and 1 patient had a large peripapillary classic CNVM extending subfoveally.
CGE
The initial group consisted of 21 eyes (14 female, 7 male) treated to 8 CGE. The patient entry characteristics are shown in Table 2 . The mean values are as follows: age, 78 years; entry lesion size, 2.4 disc areas (range 0.75-6.0); visual acuity, 20/320 (range 20/80-20/800); reading speed: 69 words per minute (range 17-141); and contrast sensitivity, 22 (range 7-100).
Seventeen eyes are reported here with up to 33 months of follow-up. Four eyes have been excluded from this group: eye 5 has been excluded due to a tear in the retinal pigment epithelium; 2 patients died of intercurrent disease after 6 months (eyes 6 and 19); and eye 7 received less than 10% of the planned radiation dose and was excluded. This left a total of 17 eyes in the 8 CGE treatment group that were included in the final evaluation. Two eyes (eyes 20 and 3) were re-treated at 6 and 12 months due to rapidly growing lesions (criteria used for re-treatment were identical to the original criteria). No growth was seen following re-treatment; however, severe visual loss occurred in both these eyes, at 9 and 12 months, respectively, following second Fig. 2 is the percentage of eyes with decreased area of leakage compared with baseline. Fig. 3 demonstrates the change in visual angle from entry in the 
The patient entry characteristics for the second group are displayed in Table 2 . Mean values were as follows: age, Radiation is a potentially beneficial agent over laser, as it allows for treatment of eyes that have poorly defined CNVM, as well as gross haemorrhage. The use of X-ray treatment for exudative ARMD has shown encouraging preliminary results ? -9 Work has also been done using brachytherapy, again with some promising results. 1S Proton beam is a form of radiation that concentrates the maximum radiation dose within a deSignated target volume, while minimising radiation to surrounding tissue. 19 This is based on the inherent absorption characteristics of protons in tissue, and accounts for the major advantage of protons over conventional X-rays in their manner of energy deposition. The point where maximum radiation is delivered is termed the Bragg peak; distal to the peak, there is a rapid decline in tissue exposure. Using the Bragg peak, the dose to normal tissue can be minimised proximal and distal to the target site. The charge carried by the protons permits a tight beam focus, unlike conventional X rays, which scatter. Outcomes in the 8 CGE group have been previously reported by Yonemoto et al. lO with up to 15 months follow-up. This initial work with eyes given 8 CGE showed favourable early results, but longer follow-up demonstrated less benefit over time. In the 14 CGE group, all eyes with entry sizes less than or equal to 8 disc areas showed neither leakage nor CNVM recurrence during follow-up but larger lesions fared worse, with increased lesion size over time and reduced visual acuity. The reasons for this poorer outcome could be that larger gliotic scars are produced and/ or irreversible damage has already occurred prior to proton treatment. The only eye treated with 14 CGE that showed severe visual loss at 3 months (eye 11) had a 12 disc area lesion complex at entry.
Our results as shown in Fig. 3 This is especially important considering that a relatively high radiation dose with documented toxicity suggests a more favourable benefit on visual function. Based on the increasing incidence of radiation retinopathy, adjustments in the total radiation dosage and / or fractionation of the dosage should be considered.
Longer-term follow-up will further define toxicity.
Although it must be emphasised that only a prospective randomised controlled study can accurately define the role of any new therapy, standardised measurement of visual function and subfoveal neovascularisation complex size strongly suggests that proton beam irradiation provides a favourable influence on the expected natural history of subfoveal CNVM secondary to ARMD.
